News |

Our growth story continues – DRA Consulting to become part of the PharmaLex Group

DRA and PharmaLex are merging to create a centre of pharma and Health Tech expertise with nearly 3,000 experts. The merger will bring synergies for the customers of both companies while helping to accelerate Nordic cooperation in the pharmaceutical market.

The merger will introduce an entirely new service package in the Nordic pharma market where a Nordic team in a single consulting company can handle marketing authorisations and launches in all the Nordic countries. DRA will become a significant part of PharmaLex’s Nordic organisation, which has previously lacked a partner with expertise in the Finnish market.

Together, a stronger strategic partner for pharmaceutical and Health Tech companies

“The merger is integral to helping us remain competitive in the future and to increasing our global market share. Together with PharmaLex we can achieve a stronger presence in the Nordic region and throughout Europe,” says DRA’s CEO Kaija Korpiaho-Haga.

“The values of PharmaLex and DRA meet, and our corporate cultures have a lot in common. We invest in our personnel as well as continuous growth and profitable development. The merger will expand and complement our service portfolio, allowing us to serve our customers even better and more comprehensively. For our experts, the merger will open up great opportunities and international career paths,” Korpiaho-Haga adds.

Both the company’s employees and founding partners will continue in their current positions after the merger. The merger has no impact on existing agreements with customers or partners.

Link to Global press release